232 related articles for article (PubMed ID: 16001244)
1. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
2. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
3. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease.
Kennedy GA; Butler J; Western R; Morton J; Durrant S; Hill GR
Bone Marrow Transplant; 2006 Jun; 37(12):1143-7. PubMed ID: 16699531
[TBL] [Abstract][Full Text] [Related]
4. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.
Onishi C; Ohashi K; Sawada T; Nakano M; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Int J Hematol; 2010 Apr; 91(3):464-70. PubMed ID: 20217287
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.
Takami A; Mochizuki K; Okumura H; Ito S; Suga Y; Yamazaki H; Yamazaki M; Kondo Y; Asakura H; Nakao S
Int J Hematol; 2006 Jan; 83(1):80-5. PubMed ID: 16443558
[TBL] [Abstract][Full Text] [Related]
6. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
7. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
Schleuning M; Judith D; Jedlickova Z; Stübig T; Heshmat M; Baurmann H; Schwerdtfeger R
Bone Marrow Transplant; 2009 May; 43(9):717-23. PubMed ID: 19011660
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
[TBL] [Abstract][Full Text] [Related]
12. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
Kasper C; Sayer HG; Mügge LO; Schilling K; Scholl S; Issa MC; Höffken K
Bone Marrow Transplant; 2004 Jan; 33(1):65-9. PubMed ID: 14704658
[TBL] [Abstract][Full Text] [Related]
13. [Benefits of mycophenolate mofetil for refractory graft-versus-host disease].
Mori M; Muroi K; Matsuyama T; Oka S; Ono Y; Yamamoto C; Uesawa M; Okabe H; Matsu H; Tatara R; Kikuchi Y; Fujiwara S; Kikuchi S; Sato K; Ueda M; Toshima M; Ozaki K; Takatoku M; Nagai T; Ozawa K
Rinsho Ketsueki; 2007 Aug; 48(8):624-31. PubMed ID: 17867298
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.
Baudard M; Vincent A; Moreau P; Kergueris MF; Harousseau JL; Milpied N
Bone Marrow Transplant; 2002 Sep; 30(5):287-95. PubMed ID: 12209350
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
Miyoshi T; Kawano-Yamamoto C; Nagashima T; Nagai T; Komatsu N; Muroi K; Ozawa K
Rinsho Ketsueki; 2003 Sep; 44(9):968-70. PubMed ID: 14577320
[TBL] [Abstract][Full Text] [Related]
16. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
20. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
